Hannah Nam

Hannah Nam

Auto-generated profile, based on publicly available information

Hannah Nam

Stanford University School of Medicine

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Antiviral Research
Verified
Journal Article
Closed access
JBJohn H. Beigel
John H. Beigel
HNHannah H. Nam
Hannah H. Nam
PAPeter L. Adams
Peter L. Adams
AKAmy Krafft
Amy Krafft
WIWilliam L. Ince
William L. Ince
ASAmy C. Sims
Amy C. Sims

26 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RLRamón Lorenzo-Redondo
Ramón Lorenzo-Redondo
HNHannah Hyochan Nam
Hannah Hyochan Nam
SRScott Roberts
Scott Roberts
LSLacy Marie Simons
Lacy Marie Simons
LJLawrence J. Jennings
Lawrence J. Jennings
EOEgon Anderson Ozer
Egon Anderson Ozer
Background: The rapid spread of SARS-CoV-2, the causative agent of Coronavirus disease 2019 (COVID- 19), has been accompanied by the emergence of distinct viral clades, though their clinical significance remains unclear. Here, we aimed to investigate the phylogenetic characteristics of SARS-CoV-2 infections in Chicago, Illinois and assess their relationship to clinical parameters. Methods: We performed whole-genome sequencing of SARS-CoV-2 isolates collected from COVID-19 patients in a Chicago healthcare system in mid-March, 2020. Using these and other publicly available sequences, we performed phylogenetic, phylogeographic, and phylodynamic analyses. Patient data was assessed for correlations between demographic or clinical characteristics and virologic features. Findings: The 88 SARS-CoV-2 genome sequences in our study separated into three distinct phylogenetic clades. Clade 1 was most closely related to viral sequences from New York, and showed evidence of rapid expansion across the US, while Clade 3 was most closely related to those in Washington state. Clade 2 was localized primarily to the Chicago area with limited evidence of expansion elsewhere. At the time of diagnosis, patients infected with Clade 1 viruses had significantly higher average viral loads in their upper airways relative to patients infected with Clade 2 viruses, independent of time to symptom onset and disease severity. Interpretation: These results show that multiple variants of SARS-CoV-2 are circulating in the Chicago area that differ in their relative viral loads in patient upper airways. These data suggest that differences in virus genotype impact viral load and may in turn influence viral transmission and spread. Funding: Dixon Family Translational Research Award, Northwestern University Clinical and Translational Sciences Institute (NUCATS), National Institute of Allergy and Infectious Diseases (NIAID)

11 April 2019 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PDF file
HSHenry Schmidt
Henry Schmidt
ADArighno Das
Arighno Das
HNHannah Nam
Hannah Nam
AYAmy Yang
Amy Yang
MIMichael G. Ison
Michael G. Ison
Objectives: Respiratory syncytial virus (RSV) is an important cause of morbidity and mortality in adults. Existing studies are limited by the number of seasons studied and most have focused on the immunocompromised.Methods: A retrospective cohort study was conducted on all adults (≥18 years) with a positive RSV molecular test admitted from 2009 to 2015 to one hospital in Chicago, IL. Epidemiologic and outcomes data were collected after IRB approval.Results: Of the 489 eligible patients, 227 had RSV A and 262 had RSV B. Patients had a median age of 61 years and comorbidity (eg, chronic lung disease [40.6%], obesity [37.8%], and cardiac disease [34.3%]). On presentation, most had cough (86.5%), fever (42.4%), and shortness of breath (38.2%). Severe disease was present in 27.6% of patients. Antibiotic was used in 76.3% inpatients and 45.8% at discharged despite few patients (4.7%) having documented bacterial infections. Supplemental oxygen and mechanical ventilation were utilized in 44.6% and 12.3%, respectively, while ICU level care was required in 26.9%. Most patients were discharged home (82.7%). Most deaths (68.4%, 13/19) were attributed to pneumonia or hypoxemia likely from RSV. Most fatal cases were seen in those with recent cancer treatment and older adults.Conclusions: Respiratory syncytial virus in hospitalized adults is associated with significant morbidity and mortality with 26.9% requiring ICU level care. Antibiotics are commonly prescribed to patients with documented RSV, and antibiotics are frequently continued after diagnosis. Novel antiviral therapies are needed for RSV to improve outcomes and potentially improve antibiotic stewardship in patients without a bacterial infection.

10 March 2024 in Journal of Hospital Medicine
Verified
Journal Article
Open access
ABAjay Bhasin
Ajay Bhasin
DNDavid C. Nguyen
David C. Nguyen
BBBenjamin J. Briggs
Benjamin J. Briggs
HNHannah H. Nam
Hannah H. Nam
Background: Respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus (PIV) hospitalize many people yearly. Though severe lower respiratory tract disease has been described in children, the elderly, and the immunocompromised, there is a gap in our understanding of RSV, hMPV, and PIV in hospitalized adults. We sought to evaluate the association of RSV, hMPV, and PIV with severe respiratory disease requiring noninvasive or mechanical ventilation and death in hospitalized adults in the United States.Methods: We conducted a retrospective, pooled, cross‐sectional study of general medicine hospitalizations in the United States from 2016 to 2019 using the National Inpatient Sample published by the Agency for Healthcare Quality and Research. We used multivariable Poisson regression to estimate the likelihood of severe respiratory disease or death. We used linear regression to estimate the mean difference in length of stay for those hospitalized with and without a respiratory virus.Results: We found that RSV (incidence rate ratio [IRR]: 1.68, 95% confidence interval [CI]: 1.61–1.74, p < .001), hMPV (IRR: 1.82, 95% CI: 1.71–1.93, p < .001), and PIV (IRR: 1.81, 95% CI: 1.68–1.94, p < .001) were independently associated with severe respiratory disease, even after adjustment. Additionally, we found the presence of a respiratory virus prolonged hospitalizations by (0.79 ± 0.27 days, p < .003) for RSV, (0.88 ± 0.28 days, p < .002) for hMPV, and (1.43 ± 0.30 days, p < .001) for PIV.Conclusions: RSV, hMPV, and PIV have a significant burden on hospitalized adults, even without classic risk factors.

1 November 2018 in Transplantation
Verified
Journal Article
Closed access
HNHannah Nam
Hannah Nam
KNKathy M. Nilles
Kathy M. Nilles
JLJosh Levitsky
Josh Levitsky
MIMichael G. Ison
Michael G. Ison
Donor-derived infections are defined as any infection present in the donor that is transmitted to 1 or more recipients. Donor-derived infections can be categorized into 2 groups: “expected” and “unexpected” infections. Expected transmissions occur when the donor is known to have an infection, such as positive serology for cytomegalovirus, Epstein Barr virus, or hepatitis B core antibody, at the time of donation. Unexpected transmissions occur when a donor has no known infection before donation, but 1 or more transplant recipients develop an infection derived from the common donor. Unexpected infections are estimated to occur in far less than 1% of solid organ transplant recipients. We will review the epidemiology, risk factors, and approaches to prevention and management of donor-derived viral infectious disease transmission in liver transplantation.

1 July 2014 in Pediatrics
Verified
Journal Article
Open access
PDF file
RCRachel Caskey
Rachel Caskey
JZJeffrey Zaman
Jeffrey Zaman
HNHannah Nam
Hannah Nam
SCSae-Rom Chae
Sae-Rom Chae
LWLauren Williams
Lauren Williams
ABAndrew D. Boyd
Andrew D. Boyd
BACKGROUND AND OBJECTIVES: Diagnostic codes are used widely within health care for billing, quality assessment, and to measure clinical outcomes. The US health care system will transition to the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM), in October 2015. Little is known about how this transition will affect pediatric practices. The objective of this study was to examine how the transition to ICD-10-CM may result in ambiguity of clinical information and financial disruption for pediatricians. METHODS: Using a statewide data set from Illinois Medicaid specified for pediatricians, 2708 International Classification of Diseases, Ninth Revision, Clinical Modification, diagnosis codes were identified. Diagnosis codes were categorized into 1 of 5 categories: identity, class-to-subclass, subclass-to-class, convoluted, and no translation. The convoluted and high-cost diagnostic codes (n = 636) were analyzed for accuracy and categorized into “information loss,” “overlapping categories,” “inconsistent,” and “consistent.” Finally, reimbursement by Medicaid was calculated for each category. RESULTS: Twenty-six percent of pediatric diagnosis codes are convoluted, which represents 21% of Illinois Medicaid pediatric patient encounters and 16% of reimbursement. The diagnosis codes represented by information loss (3.6%), overlapping categories (3.2%), and inconsistent (1.2%) represent 8% of Medicaid pediatric reimbursement. CONCLUSIONS: The potential for financial disruption and administrative errors from 8% of reimbursement diagnosis codes necessitates special attention to these codes in preparing for the transition to ICD-10-CM for pediatric practices.